Akebia Therapeutics, Inc. (AKBA) vs Century Therapeutics, Inc. (IPSC)

A side-by-side comparison of Akebia Therapeutics, Inc. and Century Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — AKBA vs IPSC

growth of $100 · dividends reinvested · last 5y
AKBA -75.2% (-24.3%/yr)IPSC -93.5% (-42.1%/yr)AKBA compounded faster over this window
050100Start $10020222023202420252026$25$6
AKBA IPSC

AKBA vs IPSC: by the numbers

  • •IPSC is the larger company ($239M vs $236M market cap).
  • •Both run net losses; IPSC's is the smaller (-8.78% vs -13.54% net margin).

Metrics side by side

Valuation

MetricAKBAIPSC
P/S ratio1.08N/A
P/B ratio9.421.03
FCF yield17.05%N/A

Profitability

MetricAKBAIPSC
Gross margin79.48%88.00%
Operating margin9.95%-13.78%
Net margin-13.54%-8.78%
ROE-118.58%-47.25%
ROIC-7.08%-43.69%

Growth (annualized)

MetricAKBAIPSC
Revenue CAGR (5Y)-0.26%N/A
Total return CAGR (5Y)-20.07%-42.05%

Frequently asked

How have AKBA and IPSC total returns compared?
Over the past 5 years, AKBA delivered -20.07% and IPSC delivered -42.05% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.